Otsuka ABILIFY contamination issue 結果共1筆

Taiwan’s FDA announces a recall of Otsuka America Pharmaceutical’s ABILIFY tablets due to contamination concerns after a notification from the U.S. FDA. The recall affects 1.789 million tablets of 5mg and 30mg doses across three batch numbers, used for treating schizophrenia and other disorders, after unclean production lines led to potential mixing with other pharmaceutical ingredients. The Taiwan FDA urges completion of the recall by May 26 and advises patients to seek alternative treatments.